For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

Development of Multigenic Lentiviral Vectors for Cell-Specific Expression of Antiangiogenic miRNAs and Protein Factors.

Retinal Gene Therapy.. 2018; 
Askou AL, Corydon TJ.
Products/Services Used Details Operation
PCR Cloning and Subcloning … The VMD2 or promotor of choice can be ordered with MluI and SalI flanking sequences from Genscript or other synthetic DNA supplier for subcloning in the pLV/CMV-miR(5, B,7)-PEDF-PE and pLV/CMV-miR(Irr)-PEDF-PE vectors [1]. 1 … Get A Quote

Abstract

Generation of lentivirus (LV)-based vectors holding multiple gene cassettes for coexpression of several therapeutic factors provides potent tools in both gene delivery studies as well as in gene therapy. Here we describe the development of such multigenic LV gene delivery vectors enabling cell-specific coexpression of antiangiogenic microRNA (miRNA) and protein factors and, if preferred, a fluorescent reporter, from RNApol(II)-driven expression cassettes orientated in a back-to-back fashion. This configuration may contribute to the development of new combination therapies for amelioration of diseases involving intraocular neovascularization including exudative age-related macular degeneration (AMD).

Keywords

AMD; Antiangiogenesis; Cell-specific expression; Coexpression; DNA cloning; Lentivirus; Multigenic vector; Retina; VEGF; miRNA